Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

NCT03303144 is registered in ClinicalTrials.gov with Rockwell Medical Technologies, Inc. as lead sponsor.

NCT NCT03303144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03303144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Lead sponsor
Rockwell Medical Technologies, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
October 1, 2017
Completion date
December 28, 2017
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease